Key Takeaways J&J won approvals for Inlexzoh/TAR-200 and Imaavy in 2025, marking major pipeline progress.JNJ is advancing nipocalimab and icotrokinra across multiple late- and mid-stage immunology trials.J&J's newer cancer drugs delivered $2.14B in nine-month 2025 sales, boosting top-line growth.Johnson & Johnson (JNJ) , like any other large drugmaker, boasts a robust R&D pipeline of drugs, with its key focus areas being immunology, oncology and neuroscience. J&J has rapidly advanced its pipeline this year, ...